Laura Angelini
Known title: DirectorCIK: 0001949708
Associated companies
Transaction History
| INVE | ▲ Buy | Grant | 18,797 | $0 | 7/30/2026 | View on chart |
| KN | ▲ Buy | Grant | 6,265 | $190K | 4/28/2026 | View on chart |
| INVE | ▲ Buy | Grant | 22,659 | $0 | 7/29/2025 | View on chart |
| KN | ▲ Buy | Grant | 11,890 | $190K | 4/29/2025 | View on chart |
| KN | ▲ Buy | Grant | 8,683 | $170K | 12/6/2024 | View on chart |
| KN | ▲ Buy | Grant | 3,473 | $68K | 12/6/2024 | View on chart |
| INVE | ▲ Buy | Grant | 14,773 | $0 | 7/29/2024 | View on chart |
| INVE | ▲ Buy | Grant | 8,904 | $0 | 8/1/2023 | View on chart |
| INVE | ▲ Buy | Grant | 3,343 | $0 | 10/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Knowles faces mixed signals with insider sale and analyst caution
Knowles is in focus this week as it prepares to attend the Midwest IDEAS Conference, with discussion building around what counts as a fair value for the stock. At the same time, several analyst pieces are highlighting concerns about the company's risk profile, with one naming Knowles among Russell 2000 names to avoid and another suggesting investors look at a different stock instead. Adding to the picture, company Director Shavers sold $260,000 worth of stock. The stock is trading near the middle of its 52-week range, with a trailing P/E well above peers and an average analyst price target of $43.75.
Knowles faces mixed signals with insider sale and analyst caution. Knowles is in focus this week as it prepares to attend the Midwest IDEAS Conference, with discussion building around what counts as a fair value for the stock. At the same time, several analyst pieces are highlighting concerns about the company's risk profile, with one naming Knowles among Russell 2000 names to avoid and another suggesting investors look at a different stock instead. Adding to the picture, company Director Shavers sold $260,000 worth of stock. The stock is trading near the middle of its 52-week range, with a trailing P/E well above peers and an average analyst price target of $43.75.